Targeting IL-22RA1 with temtokibart: A novel approach in atopic dermatitis: Phase 2a monotherapy study results

20252 citationsJournal Articlehybrid Open Access

Authors

This proof-of-concept study demonstrates that targeting the IL-22 pathway with temtokibart is clinically effective with a favorable safety profile.

Published in: Journal of Allergy and Clinical Immunology

Volume 157, Issue 3, pp. 666-676

Field-Weighted Citation Impact: 4.15